Printer Friendly

Regeneron and Sanofi partnership awarded US FDA breakthrough therapy designation for cemiplimab for squamous cell carcinoma.

M2 PHARMA-September 11, 2017-Regeneron and Sanofi partnership awarded US FDA breakthrough therapy designation for cemiplimab for squamous cell carcinoma

(C)2017 M2 COMMUNICATIONS

Biotechnology company Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi Friday jointly reported the receipt of US Food and Drug Administration (FDA) breakthrough therapy designation status for cemiplimab (REGN2810) for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC).

According to the companies, Cemiplimab, which is an investigational human, monoclonal antibody targeting PD-1, is being indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma.

Currently, cemiplimab is under clinical development and its safety and efficacy has not been fully evaluated by any regulatory authority, added the companies.

In June 2017, the companies reported positive, preliminary results for cemiplimab from two expansion cohorts involving 26 advanced CSCC patients in a Phase 1 study of nearly 400 patients, at the American Society of Clinical Oncology (ASCO) Annual Meeting

Additionally, EMPOWER-CSCC 1, a Phase 2, potentially pivotal, single-arm, open-label clinical trial of cemiplimab is currently enrolling patients with metastatic CSCC and locally advanced and unresectable CSCC, revealed the company.

Cemiplimab was discovered using Regeneron's proprietary VelocImmune technology that yields optimized fully-human antibodies and is being jointly developed by with Sanofi under a global collaboration agreement. The companies plan submitting a biologics license application for cemiplimab with the US FDA in the Q1 2018.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 11, 2017
Words:252
Previous Article:Kura Oncology reports positive top-line results from a phase two trial for tipifarnib.
Next Article:GSK exercises option to receive exclusive license for SPEAR T-cell receptor therapy from Adaptimmune.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters